Targeted tuberculin testing and treatment of latent tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 II, 2000, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC THERAPY; CLINICAL PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0034091974     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_3.ats600     Document Type: Review

References (169)

1. American Thoracic Society, Centers for Disease Control. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
2. Centers for Disease Control and Prevention. 1995. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. M.M.W.R. 44(No. RR-11):19-34.
3. Centers for Disease Control and Prevention. 1998. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. M.M.W.R. 47(No. RR-20):36-42.
4. Centers for Disease Control and Prevention. 1995. Essential components of a tuberculosis prevention and control program: recommendations of the Advisory Council for the Elimination of Tuberculosis. M.M.W.R. 44(No. RR-11):1-16.
5. Styblo, K. 1980. Recent advances in epidemiological research in tuberculosis. Adv. Tuberc. Res. 20:1-63.
6. Ferebee, S. H. 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv. Tuberc. Res. 17:28-106.
7. American Thoracic Society. 1965. Preventive treatment in tuberculosis: a statement by the Committee on Therapy. Am. Rev. Respir. Dis. 91: 297-298.
8. American Thoracic Society. 1967. Chemoprophylaxis for the prevention of tuberculosis: a statement by an Ad Hoc Committee. Am. Rev. Respir. Dis. 96:558-562.
9. Garibaldi, R. A., R. E. Drusin, S. H. Ferebee, and M. B. Gregg. 1972. Isoniazid-associated hepatitis: report of an outbreak. Am. Rev. Respir. Dis. 106:357-365.
10. American Thoracic Society, National Tuberculosis and Respiratory Disease Association, Center for Disease Control. 1971. Preventive treatment of tuberculosis. Am. Rev. Respir. Dis. 104:460-463.
11. Kopanoff, D. E., D. E. Snider, Jr., and G. J. Caras. 1979. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am. Rev. Respir. Dis. 117:991-1001.
12. American Thoracic Society, American Lung Association, Center for Disease Control. 1974. Preventive therapy of tuberculosis infection. Am. Rev. Respir. Dis. 110:371-373.
13. Taylor, W. C., M. D. Aronson, and T. L. Delbanco. 1981. Should young adults with a positive tuberculin test take isoniazid? Ann. Intern. Med. 94:808-813.
14. Mehta, J. B., A. K. Dutt, L. Harvill, and W. Henry. 1988. Isoniazid preventive therapy for tuberculosis: are we losing our enthusiasm? Chest 94:138-141.
15. American Thoracic Society, Centers for Disease Control. 1983. Treatment of tuberculosis and other mycobacterial diseases. Am. Rev. Respir. Dis. 127:790-796.
16. Salpeter, S. R. 1993. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J. Med. 159:560-564.
17. Snider, D. E., Jr., and L. S. Farer. 1984. Preventive therapy for tuberculosis infection: an intervention in need of improvement. Am. Rev. Respir. Dis. 130:355-356.
18. O'Brien, R. J., and J. H. Perriëns. 1995. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 9:665-673.
19. Advisory Council on the Elimination of Tuberculosis. 1999. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. M.M.W.R. 48(No. RR-9):1-13.
20. Sutherland, I. 1968. The ten-year incidence of clinical tuberculosis following "conversion" in 2550 individuals aged 14 to 19 years. TSRU Progress Report (KNCV, The Hague, Netherlands).
21. Ferebee, S. H., and F. W. Mount. 1962. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev. Respir. Dis. 85:490-521.
22. McKenna, M. T., E. McCray, and I. Onorato. 1995. The epidemiology of tuberculosis among foreign-born persons in the United States. 1986 to 199.3. N. Engl. J. Med. 332:1071-1076.
23. Chin, D. P., K. DeRiemer, P. M. Small, A. Ponce de Leon, R. Steinhart, G. F. Schecter, C. L. Daley, A. R. Moss, E. A. Paz, R. M. Jasmer, C. B. Agasino, and P. H. Hopewell. 1998. Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons. Am. J. Respir. Crit. Care Med. 158:1797-1803.
24. Zuber, P. L. F., M. T. McKenna, N. J. Binkin, I. M. Onorato, and K. G. Castro. 1997. Long-term risk of tuberculosis among foreign-born persons in the United States. J.A.M.A. 278:304-307.
25. Comstock, G. W., V. T. Livesay, and S. F. Woolpert. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 99:131-138.
26. Schluger, N. W., R. Huberman, N. Wolinsky, R. Dooley, W. N. Rom, and R. S. Holzman. 1997. Tuberculosis infection and disease among persons seeking social services in New York City. Int. J. Tuberc. Lung Dis. 1:31-37.
27. Sepkowitz, K. A. 1995. AIDS, tuberculosis, and the health care worker. Clin. Infect. Dis. 20:232-242.
28. Cohn, D. L., and W. M. El-Sadr. 2000. Treatment of latent tuberculosis infection. In L. B. Reichman and E. Hershfield, editors. Tuberculosis: A Comprehensive International Approach, 2nd ed. Marcel Dekker, New York. 471-502.
29. Markowitz, N., N. I. Hansen, P. C. Hopewell, J. Glassroth, P. A. Kvale, B. T. Mangura, T. C. Wilcosky, J. M. Wallace, M. J. Rosen, and L. B. Reichman. 1997. Incidence of tuberculosis in the United States among HIV-infected persons. Ann. Intern. Med. 126:123-132.
30. Selwyn, P. A., B. M. Sckell, P. Alcabes, G. H. Friedland, R. S. Klein, and E. E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. J.A.M.A. 268:504-509.
31. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
32. International Union Against Tuberculosis Committee on Prophylaxis. 1982. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull. WHO 60:555-564.
33. Falk, A., and G. F. Fuchs. 1978. Isoniazid (INH) prophylaxis with isoniazid in inactive tuberculosis: a Veterans Administration cooperative study. XII. Chest 73:44-48.
34. Steinbruck, P., D. Dankova, L. B. Edwards, B. Doster, and V. T. Livesay. 1972. The risk of tuberculosis in patients with fibrous lesions radiographically diagnosed. Bull. Int. Union Tuberc. 47:144-171.
35. Palmer, C. E., S. Jablon, and P. Q. Edwards. 1957. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am. Rev. Tuberc. 76:517-539.
36. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and British Medical Research Council. 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 145:36-41.
37. Paul, R. 1961. Silicosis in northern Rhodesia copper miners. Arch. Environ. Health 2:96-109.
38. Westerholm, P., A. Ahlmark, R. Maasing, and I. Segelberg. 1986. Silicosis and risk of lung cancer or lung tuberculosis: a cohort study. Environ. Res. 41:339-350.
39. Lundin, A. P., A. J. Adler, G. M. Berlyne, and E. A. Friedman. 1979. Tuberculosis in patients undergoing maintenance hemodialysis. Am. J. Med. 67:597-602.
40. Chia, S., M. Karim, R. K. Elwood, and J. M. FitzGerald. 1998. Risk of tuberculosis in dialysis patients: a population-based study. Int. J. Tuberc. Lung Dis. 2:989-991.
41. Andrew, O. T., P. Y. Schoenfeld, P. C. Hopewell, and M. H. Humphreys. 1980. Tuberculosis in patients with end-stage renal disease. Am. J. Med. 68:59-65.
42. Pablos-Méndez, A., J. Blustein, and C. A. Knirsch. 1997. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am. J. Public Health 87:574-579.
43. Boucot, K. R., E. S. Dillon, D. A. Cooper, and P. Meier. 1952. Tuberculosis among diabetics: the Philadelphia Survey. Am. Rev Tuberc. 65(Suppl.):1-50.
44. Oscarsson, P. N., and H. Silwer. 1958. Incidence of pulmonary tuberculosis among diabetics: search among diabetics in the county of Kristianstad. Acta Med. Scand. 161(Suppl. 335):23-48.
45. Thorn, P. A., V. S. Brookes, and J. A. H. Waterhouse. 1956. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. Br. Med. J. 1:603-608.
46. Snider, D. E., Jr. 1985. Tuberculosis and gastrectomy. Chest 87:414-415.
47. Steiger, Z., W. O. Nickel, G. J. Shannon, E. G. Nedwicki, and R. F. Higgins. 1976. Pulmonary tuberculosis after gastric resection. Am. J. Surg. 131:668-671.
48. Pickleman, J. R., L. S. Evans, J. M. Kane, and R. J. Freeark. 1975. Tuberculosis after jejunoileal bypass for obesity. J.A.M.A. 234:744.
49. Bruce, R. M., and L. Wise. 1977. Tuberculosis after jejunoileal bypass for obesity. Ann. Intern. Med. 87:574-576.
50. Lichtenstein, I. H., and R. R. MacGregor. 1983. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev. Infect. Dis. 5:216-226.
51. Muñoz, P., J. Palomo, M. Muñoz, M. Rodirguez-Creixéms, T. Pelaez, and E. Bouza. 1995. Tuberculosis in heart transplant recipients. Clin. Infect. Dis. 21:398-402.
52. Korner, M. M., N. Hirata, G. Tenderich, K. Minami, H. Mannebach, K. Kleesiek, and R. Körfer. 1997. Tuberculosis in heart transplant recipients. Chest 111:365-369.
53. Feld, R., G. P. Bodey, and D. Groschel. 1976. Mycobacteriosis in patients with malignant disease. Arch. Intern. Med. 136:67-70.
54. Kaplan, M. H., D. Armstrong, and P. Rosen. 1974. Tuberculosis complicating neoplastic disease: a review of 201 cases. Cancer 33:850-858.
55. Schatz, M., R. Patterson, R. Kloner, and J. Falk. 1976. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann. Intern. Med. 84:261-265.
56. Bovornkitti, S., P. Kangsadai, P. Sathirapat, and P. Oonsombatti. 1960. Reversion and reconversion rate of tuberculin skin test reactions in correlation with use of prednisone. Dis. Chest 38:51-55.
57. Bateman, E. D. 1993. Is tuberculosis chemoprophylaxis necessary for patients receiving corticosteroids for respiratory disease? Respir. Med. 87:485-487.
58. Kim, H. A., C. D. Yoo, H. J. Baek, E. B. Lee, C. Ahn, J. S. Han, S. Kim, J. S. Lee, K. W. Choe, and Y. W. Song. 1998. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin. Exp. Rheumatol. 16:9-13.
59. Friedman, L. N., M. T. Williams, P. S. Tejinder, and T. R. Frieden. 1996. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N. Engl. J. Med. 334:828-833.
60. Buskin, S. E., J. L. Gale, N. S. Weiss, and C. M. Nolan. 1994. Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990. Am. J. Public Health 84:1750-1756.
61. Centers for Disease Control. 1989. A strategic plan for the elimination of tuberculosis in the United States. M.M.W.R. 38(Suppl. S-3):1-25.
62. Goldberg, B. W. 1998. Managed care and public health departments: who is responsible for the health of the population? Ann. Rev. Public Health 19:527-537.
63. Nelson, K. R., H. Bui, and J. H. Samet. 1997. Screening in special populations: a "case study" of recent Vietnamese immigrants. Am. J. Med. 102:435-440.
64. Nolan, C. M., L. Roll, S. V. Goldberg, and A. M. Elarth. 1997. Directly observed isoniazid preventive therapy for released jail inmates. Am. J. Respir. Crit. Care Med. 155:583-586.
65. Nazar-Stewart, V., and C. M. Nolan. 1992. Results of a directly-observed intermittent isoniazid preventive therapy program in a shelter for homeless men. Am. Rev. Respir. Dis. 146:57-60.
66. Bock, N. N., B. S. Metzger, M. Tapia, and H. M. Blumberg. 1999. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am. J. Respir. Crit. Care Med. 159:295-300.
67. Gourevitch, M. N., P. Alcabes, W. C. Wasserman, and P. S. Arno. 1998. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int. J. Tuberc. Lung Dis. 2:531-540.
68. Perlman, D. C., M. P. Perkins, N. Solomon, L. Kochems, D. C. Des Jarlais, and D. Paone. 1997. Tuberculosis screening at a syringe exchange program. Am. J. Public Health 87:862-863.
69. Schluger, N. W., R. Huberman, I. Holzman, W. N. Rom, and D. I. Cohen. 1999. Screening for infection and disease as a tuberculosis control measure among indigents in New York City, 1994-1997. Int. J. Tuberc. Lung Dis. 3:281-286.
70. American Thoracic Society, Centers for Disease Control and Prevention. 2000. Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 161:1376-1395.
71. Huebner, R. E., W. Schein, and J. B. Bass, Jr. 1993. The tuberculin skin test. Clin. Infect. Dis. 17:968-975.
72. Cauthen, G. W., and S. E. Valway. 1994. Tuberculin reactions read at 2 and 7 days. Am. J. Respir. Crit. Care Med. 149(Pt. 2):A101.
73. Rose, D. N., C. B. Schecter, and J. J. Adler. 1995. Interpretation of the tuberculin skin test. J. Gen. Intern. Med. 10:635-642.
74. Sepulveda, R. L., X. Ferrer, C. Latrach, and R. U. Sorensen. 1990. The influence of Calmette-Guérin Bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am. Rev. Respir. Dis. 142:24-28.
75. McKay, A., A. Kraut, C. Murdzak, and A. Yassi. 1999. Determinants of tuberculin reactivity among health care workers: interpretation of positivity following BCG vaccination. Can. J. Infect. Dis. 10:134-139.
76. Graham, N. M. H., K. E. Nelson, L. Solomon, M. Bonds, R. T. Rizzo, J. Scavotto, J. Astemborski, and D. Vlahov. 1992. Prevalence of tuberculin positivity and skin test anergy in HIV-I seropositive and seronegative intravenous drug users. J.A.M.A. 267:369-373.
77. Centers for Disease Control and Prevention. 1997. Anergy skin testing and tuberculosis preventive therapy for HV-1 infected persons: revised recommendations. M.M.W.R. 46(No. RR-15):1-10.
78. Ferebee, S. H., and C. E. Palmer. 1956. Prevention of experimental tuberculosis with isoniazid. Am. Rev Tuberc. Pulmon. Dis. 73:1-18.
79. Comstock, G. W., and S. H. Ferebee. 1970. How much isoniazid is needed for prophylaxis? Am. Rev. Respir. Dis. 101:780-782.
80. Comstock, G. W. 1999. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int. J. Tuberc. Lung Dis. 3:847-850.
81. Snider, D.E., Jr., G. J. Caras, and J. P. Koplan. 1986. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. J.A.M.A. 255:1579-1583.
82. American Thoracic Society, Centers for Disease Control. 1986. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. 134:355-363.
83. Pape, J. W., S. S. Jean, J. L. Ho, A. Hafher, and W. D. Johnson, Jr. 1993. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342:268-272.
84. Whalen, C. C., J. L. Johnson, A. Okwera, D. L. Hom, R. Huebner, P. Mugyenyi, R. D. Mugerwa, and J. J. Ellner. 1997. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N. Engl. J. Med. 337:801-808.
85. Hawken, M. P., H. K. Meme, L. C. Elliot, J. M. Chakaya, J. S. Morris, W. A. Githui, E. S. Juma, J. A. Odhiambo, L. N. Thiong'o, J. N. Kimari, E. N. Ngugi, J. J. Bwayo, C. F. Gilks, F. A. Plummer, J. D. H. Porter, P. P. Nunn, and K. P. W. J. McAdam. 1997. Isoniazid preventive therapy for tuberculosis in HIV-I-infected adults: results of a randomized controlled trial. AIDS 11:875-882.
86. Mwinga, A., M. Hosp, P. Godfrey-Faussett, M. Quigley, P. Mwaba, B. N. Mugala, O. Nyirenda, N. Luo, J. Pobee, A. M. Elliott, K. P. W. J. McAdam, and J. D. H. Porter. 1998. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 12:2447-2457.
87. Gordin, F. M., J. P. Matts, C. Miller, L. S. Brown, R. Hafner, S. L. John, M. Klein, A. Vaughn, C. L. Besch, G. Perez, S. Szabo, and W. El-Sadr. 1997. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N. Engl. J. Med. 337:315-320.
88. Bucher, H. C., L. E. Griffith, G. H. Guyatt, P. Sudre, M. Naef, P. Sendi, and M. Battegay. 1999. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13:501-507.
89. Mitchell, J. R., H. J. Zimmerman, K. G. Ishak, U. P. Thorgeirsson, J. A. Timbrell, W. R. Snodgrass, and S. D. Nelson. 1976. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann. Intern. Med. 84:181-192.
90. Comstock, G. W. 1986. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. J.A.M.A. 256:2729-2730.
91. Snider, D.E., Jr., and G. J. Caras. 1992. Isoniazid-associated hepatitis deaths: a review of available information. Am. Rev. Respir. Dis. 145: 494-497.
92. Franks, A. L., N. J. Binkin, D. E. Snider, Jr., W. M. Rokaw, and S. Becker. 1989. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Pub. Health Rep. 104:151-155.
93. Murphy, R., R. Swartz, and P. B. Watkins. 1990. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann. Intern. Med. 113:799-800.
94. Burk, R. F., K. E. Hill, R. W. Hunt, and A. E. Martin. 1990. Isoniazid potentiation of acetaminophen hepatotoxicity in the rat and 4-methylpyrazole inhibition of it. Res. Commun. Chem. Path. Pharmacol. 69:115-158.
95. Millard, P. S., T. C. Wilcosky, S. J. Reade-Christopher, and D. J. Weber. 1996. Isoniazid-related fatal hepatitis. West J. Med. 164:486-491.
96. Moulding, T. S., A. G. Redeker, and G. C. Kanel. 1989. Twenty isoniazid-associated deaths in one state. Am. Rev. Respir. Dis. 140:700-705.
97. Centers for Disease Control and Prevention. 1993. Severe isoniazid-associated hepatitis - New York, 1991-1993. M.M.W.R. 42:545-547.
98. Leff, D. R., and A. R. Leff. 1997. Tuberculosis control policies in major metropolitan health departments in the United States. Am. J. Respir. Crit. Care Med. 156:1487-1494.
99. Nolan, C. M., S. V. Goldberg, and S. E. Buskin. 1999. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. J.A.M.A. 281:1014-1018.
100. Tsevat, J., W. C. Taylor, J. B. Wong, and S. G. Pauker. 1988. Isoniazid for the tuberculin reactor: take it or leave it. Am. Rev. Respir. Dis. 137:215-220.
101. Rose, D. N., C. B. Schechter, and A. L. Silver. 1986. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. J.A.M.A. 256:2709-2713.
102. Salpeter, S. R., G. D. Sanders, E. E. Salpeter, and D. K. Owens. 1997. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 yr of age: a risk-benifit and cost effectiveness analysis. Ann. Intern. Med. 127:1051-1061.
103. Colice, G. L. 1990. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch. Intern. Med. 150:2517-2522.
104. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
105. Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551.
106. Dhillon, J., J. M. Dickinson, K. Sole, and D. A. Mitchison. 1996. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob. Agents Chemother. 40:552-555.
107. Jabes, D., C. Della Bruna, R. Rossi, and P. Olliaro. 1994. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrob. Agents Chemother. 38:2346-2350.
108. Ormerod, L. P. 1998. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch. Dis. Child 78:169-171.
109. Joint Tuberculosis Committee of the British Thoracic Society. 1998. Chemotherapy and management of tuberculosis in the United Kingdom. Thorax 53:536-548.
110. Halsey, N. A., J. S. Coberly, and J. Desormeaux, P. Losikoff, J. Atkinson, L. H. Moulton, M. Contave, M. Johnson, H. Davis, L. Geiter, E. Johnson, R. Huebner, R. Boutos, and R. E. Chaisson. 1998. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-1 infected persons: an international randomized trial. Lancet 351:786-792.
111. Gordin, F. M., R. E. Chaisson, J. P. Matts, C. Miller, M. de Lourdes Garcia, R. Hafner, J. L. Valdespino, J. Coberly, M. Schechter, A. J. Klukowicz, M. A. Barry, and R. J. O'Brien. 2000. An international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons. J.A.M.A. 283: 1445-1450.
112. Geiter, L. J., R. J. O'Brien, and D. E. Kopanoff. 1990. Short-course preventive therapy for tuberculosis (abstract). Am. Rev. Respir. Dis. 141(Pt. 2):A437.
113. Geiter, L. J. 1997. Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-momth regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six months-isoniazid [thesis]. Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD.
114. Combs, D. L., R. J. O'Brien, and L. J. Geiter. 1990. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann. Intern. Med. 112:397-406.
115. Grazcyk, J., R. J. O'Brien, E. Bek, H. Nimerowsak, and L. J. Geiter. 1991. Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results from a pilot study in Poland (abstract). Am. Rev. Respir. Dis. 143:A119.
116. Magdorf, K., A. F. Arizzi-Ruche, L. J. Geiter, R. J. O'Brien, and U. Wahn. 1994. Compliance and tolerance of new antituberculotic shortterm chemoprevention regimes in childhood: a pilot study. Pneumologie 48:761-764.
117. Snider, D. E., and M. D. Hutton. 1989. Improving patient compliance in tuberculosis treatment programs. Department of Health and Human Services, CDC, Atlanta, GA.
118. Sumartojo, E. 1993. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am. Rev. Respir. Dis. 147:1311-1320.
119. Carey, J. W., M. J. Oxtoby, L. P. Nguyen, V. Huynh, M. Morgan, and M. Jeffery. 1997. Tuberculosis beliefs among recent Vietnamese refugees in New York State. Public Health Rep. 112:66-72.
120. Morisky, D. E., C. K. Malotte, P. Choi, P. Davidson, S. Rigler, B. Sugland, and M. Langer. 1990. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ. Q. 17:253-267.
121. Harborview Medical Center, University of Washington. Ethnic Medicine Guide. 〈http://www.hslib.washington.edu/clinical/ethnomed/〉
122. White, M. C., J. P. Tulsky, P. Reilly, H. W. McIntosh, T. M. Hoynes, and J. Goldenson. 1998. A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. Int. J. Tuberc. Lung Dis. 2:506-512.
123. Heal, G., R. K. Elwood, and J. M. FitzGerald. 1998. Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia. Int. J. Tuberc. Lung Dis. 2:979-983.
124. Wobeser, W., T. To, and V. H. Hoeppner. 1989. The outcome of chemoprophylaxis on tuberculosis prevention in the Canadian Plains Indian. Clin. Invest Med. 12:149-153.
125. Kohn, M. R., M. R. Arden, J. Vasilakis, and I. R. Shenker. 1996. Directly observed preventive therapy: turning the tide against tuberculosis. Arch. Pediatr. Adolesc. Med. 150:727-779.
126. Judson, F. N., J. A. Sbarbaro, J. M. Tapy, and D. L. Cohn. 1983. Tuberculosis screening: evaluation of a food handler's program. Chest 83:879-82.
127. Cohn, D. L., B. J. Catlin, K. L. Peterson, F. N. Judson, and J. A. Sbarbaro. 1990. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann. Intern. Med. 112:407-415.
128. Shafran, S. D., J. Singer, D. P. Zarowny, J. Deschênes, P. Phillips, F. Turgeon, F. Y. Aoki, E. Toma, M. Miller, R. Duperval, C. Lemieux, and W. F. Schlech, III. 1998. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobaeterium avium complex bacteremia: a multivariate analysis. J. Infect. Dis. 77:252-255.
129. Sun, E., M. Heath-Chiozzi, D. W. Cameron, A. Hsu, R. G. Granneman, C. J. Maurath, and J. M. Leinard. 1996. Concurrent fitonavir and fifabutin increases risk of rifabutin-associated adverse events [Abstract no. MoB171]. In Programs and abstracts of the XI International Conference on AIDS. Vancouver, BC, Canada. 18.
130. McGregor, M. M., P. Olliaro, L. Wolmarans, B. Mabuza, M. Bredell, M. Felten, and B. Fourie. 1996. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 154:1462-1467.
131. Vernon, A., W. Burman, D. Benator, A. Khan, and L. Bozeman. 1999. Acquired riifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 353:1843-1847.
132. Jarvis, B., and H. M. Lamb. 1998. Rifapentine. Drugs 56:607-616.
133. Good, J. T., Jr., M. D. Isemen, P. T. Davidson, S. Lakshnminarayan, and S. A. Sahn. 1981. Tuberculosis in association with pregnancy. Am. J. Obstet. Gynecol. 140:492-498.
134. Carter, E. J., and S. Mates. 1994. Tuberculosis during pregnancy: the Rhode Island experience, 1987 to 1991. Chest 106:1466-1470.
135. Smith, J. K., E. A. Caspery, and E. J. Field. 1972. Lymphocyte reactivity to antigen in pregnancy. Am. J. Obstet. Gynecol. 113:602-606.
136. Montgomery, W. P., R. C. Young, Jr., and M. P. Allen. 1968. The tuberculin test in pregnancy. Am. J. Obstet. Gynecol. 100:829-831.
137. Present, P. A., and G. W. Comstock. 1975. Tuberculin sensitivity in pregnancy. Am. Rev. Respir. Dis. 112:413-415.
138. Snider, D. E., Jr., P. M. Layde, M. W. Johnson, and M. A. Lyle. 1980. Treatment of tuberculosis during pregnancy. Am. Rev. Respir. Dis. 122:65-69.
139. Cantwell, M. F., Z. M. Shehab, A. M. Costello, L. Sands, W. F. Green, E. P. Ewing, S. E. Valway, and I. M. Onorato. 1994. Brief report: congenital tuberculosis. N. Engl. J. Med. 330:1051-1054.
140. Scheinhorn, D. J., and V. A. Angelillo. 1977. Antituberculous therapy in pregnancy: risks to the fetus. West. J. Med. 127:195-198.
141. Eggermont, E., N. Logghe, W. Van De Casseye, M. Casteels-Van Daele, J. Jaeken, J. Cosemans, M. Verstraete, and M. Renaer. 1976. Hemorrhagic disease of the newborn in the offspring of rifampin and isoniazid treated mothers. Acta. Paediatr. Belg. 29:87-89.
142. Centers for Disease Control and Prevention. 1999. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). M.M.W.R. 48(No. RR-10):13-14.
143. Snider, D. E., Jr., and K. E. Powell. 1984. Should women taking antituberculosis drugs breast-feed? Arch. Intern. Med. 144:589-590.
144. Miller, F. J. W., R. M. E. Seale, and N. M. Taylor. 1963. Tuberculosis in children. Little Brown, Boston, MA. 77.
145. Comstock, G. W., L. M. Hammes, and A. Pio. 1969. Isoniazid prophylaxis in Alaskan boarding schools: a comparison of two doses. Am. Rev. Respir. Dis. 100:773-779.
146. Mount, F. W., and S. H. Ferrebee. 1961. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N. Engl. J. Med. 265:713-721.
147. O'Brien, R. J., M. W. Long, F. S. Cross, M. A. Lyle, and D. E. Snider, Jr. 1983. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics 72:491-499.
148. Stein, M. T., and D. Liang. 1979. Clinical hepatotoxicity of isoniazid in children. Pediatrics 64:499-505.
149. Villarino, M. E., R. Ridzon, P. C. Weismuller, M. Elcock, R. M. Maxwell, J. Meador, P. J. Smith, M. L. Carson, and L. J. Geiter. 1997. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am. J. Respir. Crit Care Med. 155:1735-1738.
150. American Academy of Pediatrics. 2000. Tuberculosis. In Red Book: Report of the Committee on Infectious Diseases, 25th ed. American Academy of Pediatrics, Elk Grove Village, IL. (In press)
151. Koplan, J. P., and L. S. Farer. 1980. Choice of preventive treatment for isoniazid-resistant tuberculosis infection: use of decision analysis and the Delphi technique. J.A.M.A. 244:2736-2740.
152. Bailey, W. C., R. B. Byrd, J. C. Glassroth, P. C. Hopewell, and L. B. Reichman. 1985. Preventive treatment of tuberculosis. Chest 87:1285-1325.
153. Polesky, A., H. W. Farbe, D. J. Gottlieb, H. Park, S. Levinson, J. J. O'Connell, B. McInnis, R. L. Nieves, and J. Bernardo. 1996. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am. J. Respir. Crit. Care Med. 154:1473-1477.
154. Livengood, J. R., T. G. Sigler, L. R. Foster, J. G. Bobst, and D. E. Snider. 1985. Isoniazid-resistant tuberculosis: a community outbreak and report of a rifampin prophylaxis failure. J.A.M.A. 253:2847-2849.
155. Pablos-Mendez, A., M. C. Raviglione, A. Laszlo, N. B. Binkin, H. L. Rieder, F. Bustreo, D. L. Cohn, C. S. B. Lambregts-Van Weezenbeek, S. J. Kim, P. Chaulet, and P. Nunn. 1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Engl. J. Med. 338:1641-1649.
156. Passannante, M. R., C. T. Gallagher, and L. B. Reichman. 1994. Preventive therapy for contacts of multidrug-resistant tuberculosis: a Delphi survey. Chest 106:431-134.
157. Centers for Disease Control and Prevention. 1992. Management of persons exposed to multidrug-resistant tuberculosis. M.M.W.R. 41(No. RR-11):61-71.
158. Ridzon, R., J. Meador, R. Maxwell, K. Higgins, P. Weismuller, and I. M. Onorato. 1997. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin. Infect. Dis. 24:1264-1265.
159. Trébucq, A. 1997. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int. J. Tuberc. Lung Dis. 1:12-15.
160. Gough, A. W., O. B. Kasali, R. E. Sigler, and V. Baragi. 1992. Quinolone arthropathy - acute toxicity to immature articular cartilage. Toxicol. Pathol. 20:436-449.
161. Danišovičova, A., M. Brezina, S. Belan, H. Kayserova, E. Kaiserova, I. Hruskovic, K. Orosová, S. Dluholucky, K. Gaĺova E. Mathéova, I. Marinová, and V. Krěméry, Jr. 1994. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy - a mullicenter survey. Chemotherapy 40:209-214.
162. Steiner, P., and M. Rao. 1993. Drug-resistant tuberculosis in children. Semin. Pediatr. Infect. Dis. 4:275-282.
163. Swanson, D. S., and J. R. Starke. 1995. Drug-resistant tuberculosis in pediatrics. Pediatr. Clin. North Am. 42:553-581.
164. Centers for Disease Control and Prevention. 1996. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. M.M.W.R. 45(No. RR-4):8-9.
165. Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med. 150:1355-1362.
166. Reddy, M. V., J. Luna-Herrera, D. Daneluzzi, and P. R. Gangadhararn. 1996. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tuberc. Lung Dis. 77:154-159.
167. Stover, C. K., Y. Yuan, P. G. Warrener, D. R. VanDevanter, D. R. Sherman, M. H. Langhorne, K. Tanaka, C. E. Barry, and W. R. Baker. 1999. A novel compound series and development candidate for the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 159(Suppl.):AI6.
168. Centers for Disease Control and Prevention. 1998. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). M.M.W.R. 47(No. RR-13): 1-6.
169. Centers for Disease Control and Prevention. 2000. Notice to Readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis in HIV-infected persons taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. M.M.W.R. 49:185-189.